№ lp_2_3_36677
Patient information leaflet outlining indications, administration, risks, contraindications and driving regulations related to gliclazide treatment for diabetes.
Medicine name: Gliclazide
Therapeutic class: Oral hypoglycaemic agent
Indications: Type 2 diabetes; monogenic diabetes; steroid-induced diabetes
Form: Tablet
Administration: Once or twice daily with food
Dose adjustment: According to blood glucose levels under medical supervision
Common adverse effects: Nausea; diarrhoea; constipation; weight gain
Serious adverse effects: Hypoglycaemia; liver dysfunction; blood cell disorders
Contraindications: Type 1 diabetes; severe kidney disease; severe liver disease; pregnancy; breastfeeding; concomitant miconazole use; porphyria
Driving regulations: Notification required to DVLA for Group 2 licence holders
Monitoring requirements: Regular blood glucose monitoring; mandatory monitoring for Group 2 drivers during driving
Issuing institution: Edinburgh Centre for Endocrinology and Diabetes
Document type: Patient information leaflet
Geographical reference: United Kingdom
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.